Canterbury DHB
|
|
|
This is a rare MPN characterised by chronic neutrophilia, and marrow hypercellularity due to granulocyte proliferation and hepatosplenomegaly.
CNL:
See Tefferi A, et al. (2016), table 1, page 3 for diagnostic criteria for CNL.
In CNL, a chronic phase, accelerated phase and a blast phase can be recognised (like CML). The chronic phase disease has typically been treated as needed with cytoreductive therapy, such as hydroxyurea.
Disease acceleration often manifests with:
Blast transformation, which to date has been exclusively reported as myeloid, occurs in a significant proportion (20%) of patients at a median of 21 months from diagnosis. The reported median survival of all patients is under 2 years.
|
Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document.
|
|
Topic Code: 532917
Disclaimer